These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

510 related items for PubMed ID: 23294160

  • 1. Flecainide acetate for the treatment of atrial and ventricular arrhythmias.
    Apostolakis S, Oeff M, Tebbe U, Fabritz L, Breithardt G, Kirchhof P.
    Expert Opin Pharmacother; 2013 Feb; 14(3):347-57. PubMed ID: 23294160
    [Abstract] [Full Text] [Related]

  • 2. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR, Buxton AE, Rinkenberger RL, Nademanee K, Heilman JM, Kienzle MG.
    Am J Cardiol; 1996 Jan 25; 77(3):72A-82A. PubMed ID: 8607395
    [Abstract] [Full Text] [Related]

  • 3. [Life-threatening ventricular tachycardia during flecainide treatment for symptomatic atrial fibrillation in a patient with a structural cardiac disorder].
    Rienstra M, Wiesfeld AC, van Veldhuisen DJ, van Gelder IC.
    Ned Tijdschr Geneeskd; 2006 May 06; 150(18):1027-31. PubMed ID: 16715868
    [Abstract] [Full Text] [Related]

  • 4. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM, Verma A, Talajic M, Nattel S, Dorian P, CCS Atrial Fibrillation Guidelines Committee.
    Can J Cardiol; 2011 May 06; 27(1):47-59. PubMed ID: 21329862
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of class IC antiarrhythmic agents for the treatment of coexisting supraventricular and ventricular tachycardia.
    Rinkenberger RL, Naccarelli GV, Berns E, Dougherty AH.
    Am J Cardiol; 1988 Aug 25; 62(6):44D-55D. PubMed ID: 3136636
    [Abstract] [Full Text] [Related]

  • 6. Safety of flecainide.
    Tamargo J, Capucci A, Mabo P.
    Drug Saf; 2012 Apr 01; 35(4):273-89. PubMed ID: 22435343
    [Abstract] [Full Text] [Related]

  • 7. Meta-analysis of flecainide safety in patients with supraventricular arrhythmias.
    Wehling M.
    Arzneimittelforschung; 2002 Apr 01; 52(7):507-14. PubMed ID: 12189773
    [Abstract] [Full Text] [Related]

  • 8. The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events.
    Almroth H, Andersson T, Fengsrud E, Friberg L, Linde P, Rosenqvist M, Englund A.
    J Intern Med; 2011 Sep 01; 270(3):281-90. PubMed ID: 21635583
    [Abstract] [Full Text] [Related]

  • 9. [Drug therapy of cardiac arrhythmias 199].
    Dietz A, Manz M.
    Fortschr Med; 1997 Nov 30; 115(33):32, 34-6, 38. PubMed ID: 9480278
    [Abstract] [Full Text] [Related]

  • 10. [Flecainide and anti-arrhythmia therapy].
    Croce L, Romano S, Pozzoni L, Lomuscio A.
    Minerva Med; 1988 Mar 30; 79(3):229-34. PubMed ID: 3129677
    [Abstract] [Full Text] [Related]

  • 11. Flecainide toxicity in a neonate with supraventricular tachycardia.
    Zeigler VL, Peterson J.
    Heart Lung; 1991 Nov 30; 20(6):689-91. PubMed ID: 1960074
    [Abstract] [Full Text] [Related]

  • 12. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M, Cullen MT, Casadei G.
    Eur Heart J; 1995 Dec 30; 16(12):1943-51. PubMed ID: 8682031
    [Abstract] [Full Text] [Related]

  • 13. Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia.
    Luedtke SA, Kuhn RJ, McCaffrey FM.
    Ann Pharmacother; 1997 Nov 30; 31(11):1347-59. PubMed ID: 9391691
    [Abstract] [Full Text] [Related]

  • 14. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysiology Group.
    Fish FA, Gillette PC, Benson DW.
    J Am Coll Cardiol; 1991 Aug 30; 18(2):356-65. PubMed ID: 1906902
    [Abstract] [Full Text] [Related]

  • 15. Targeted pharmacological reversal of electrical remodeling after cardioversion--rationale and design of the Flecainide Short-Long (Flec-SL) trial.
    Kirchhof P, Fetsch T, Hanrath P, Meinertz T, Steinbeck G, Lehmacher W, Breithardt G.
    Am Heart J; 2005 Nov 30; 150(5):899. PubMed ID: 16290956
    [Abstract] [Full Text] [Related]

  • 16. Flecainide and encainide.
    Furlanello F, Vergara G, Bettini R, Mosna G, Gramegna L, Disertori M.
    Eur Heart J; 1987 Mar 30; 8 Suppl A():33-40. PubMed ID: 3107989
    [Abstract] [Full Text] [Related]

  • 17. Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
    Pritchett EL, Wilkinson WE.
    Am J Cardiol; 1991 May 01; 67(11):976-80. PubMed ID: 1902055
    [Abstract] [Full Text] [Related]

  • 18. Antiarrhythmic agents for chronic ventricular arrhythmias.
    Nestico PF, Morganroth J.
    Compr Ther; 1987 Apr 01; 13(4):26-35. PubMed ID: 3105950
    [Abstract] [Full Text] [Related]

  • 19. Serial cardioversion by class IC Drugs during 4 months of persistent atrial fibrillation in the goat.
    Eijsbouts S, Ausma J, Blaauw Y, Schotten U, Duytschaever M, Allessie MA.
    J Cardiovasc Electrophysiol; 2006 Jun 01; 17(6):648-54. PubMed ID: 16836716
    [Abstract] [Full Text] [Related]

  • 20. [Tachycardia with wide QRS. Limitations of electrocardiographic criteria in patients treated with anti-arrhythmia agents].
    Le Davay M, Victor J, Dupuis JM, Merheb M, Tran P, Tadeï A.
    Ann Cardiol Angeiol (Paris); 1994 May 01; 43(5):253-5. PubMed ID: 8074416
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.